

<b>Patient Name</b> SAMPLEREP,EGFR	<b>Patient ID</b> SA00043353	<b>Age</b> 45	<b>Gender</b> F	<b>Order #</b> SA00043353
<b>Ordering Phys</b>				<b>DOB</b> 06/10/1966
<b>Client Order #</b> SA00043353	<b>Account Information</b>			<b>Report Notes</b>
<b>Collected</b> 02/08/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
<b>Printed</b> 02/10/2012 10:11				

Test	Flag	Results	Unit	Reference Value	Perform Site*
<b>EGFR Gene, Mutation Analysis, Tumor</b>			REPORTED 02/09/2012 14:20		
Specimen		Tissue			MCR
Specimen ID		1037730			MCR
Order Date		09 Feb 2012 14:02			MCR
Reason for Referral		Evaluate tumor DNA for presence of a mutation in exons 18-21 of the EGFR gene.			MCR
Method		A PCR based assay employing allele specific amplification was used to test for the presence of 29 mutations within exons 18-21 of the EGFR gene (G719A, G719S, G719C in exon 18; small deletions in exon 19; T790M, S768I, and small insertions in exon 20; and L858R and L861Q in exon 21). Mutation nomenclature is based on GenBank accession number; NM005228.3.			MCR
Result		Tumor type: Non-small cell lung cancer EGFR status: Wild-type			MCR
Interpretation		Current data suggest that patients with non-small cell lung cancer with mutations in the tyrosine kinase domain (exons 18-21) of EGFR may respond to EGFR tyrosine kinase inhibitor therapies. Thus, the absence of an EGFR mutation within this tumor specimen suggests that these therapies may have limited therapeutic value for this patient.  The predictive value of EGFR testing applies to EGFR tyrosine kinase inhibitor therapies, not to other therapeutic agents.  This result does not rule out the presence of a mutation that may be present but below the limits of detection for this assay (approximately 10%) or an EGFR mutation that is not part of this panel. It is estimated that this panel detects greater than 95% of pathogenic mutations in exons 18-21 of the EGFR gene.  Consideration of these results, in light of other clinical information, may aid in clinical management decisions for this patient.  CAUTIONS: Rare polymorphisms exist that could lead to false negative or false positive results. Test results should be			MCR

\*\*\*Performing Site Legend on Last Page of Report\*\*\*

<b>Patient Name</b> SAMPLEREP,EGFR	<b>Collection Date and Time</b> 02/08/2012 13:00	<b>Report Status</b> Final
Page 1 of 2		>> Continued on Next Page >>

\* Report times for Mayo performed tests are CST/CDT

<b>Patient Name</b> SAMPLEREP,EGFR	<b>Patient ID</b> SA00043353	<b>Age</b> 45	<b>Gender</b> F	<b>Order #</b> SA00043353
<b>Ordering Phys</b>				<b>DOB</b> 06/10/1966
<b>Client Order #</b> SA00043353	<b>Account Information</b>			<b>Report Notes</b>
<b>Collected</b> 02/08/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
<b>Printed</b> 02/10/2012 10:11				

Test	Flag	Results	Unit	Reference Value	Perform Site*
------	------	---------	------	-----------------	---------------

interpreted in context of clinical findings, tumor sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

For research use only.

Reviewed By:  
Release Date

Benjamin Robert Kipp  
09 Feb 2012 14:17

MCR  
MCR

\* Performing Site:

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.
-----	---	--

<b>Patient Name</b> SAMPLEREP,EGFR	<b>Collection Date and Time</b> 02/08/2012 13:00	<b>Report Status</b> Final
Page 2 of 2		** End of Report **

\* Report times for Mayo performed tests are CST/CDT